{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T16:11:07Z","timestamp":1779120667232,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40262-026-01629-1","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:51:31Z","timestamp":1773773491000},"page":"709-718","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics of Asciminib 200 mg in the Presence of a Strong CYP3A4 Inducer, Phenytoin, in Healthy Participants"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1033-2716","authenticated-orcid":false,"given":"Matthias","family":"Hoch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7720-9475","authenticated-orcid":false,"given":"Amanda J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7121-4394","authenticated-orcid":false,"given":"Felix","family":"Huth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seshulatha","family":"Jamalapuram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2586-3577","authenticated-orcid":false,"given":"Ioannis","family":"Loisios-Konstantinidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1543-6460","authenticated-orcid":false,"given":"Michelle","family":"Quinlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athina","family":"Kranidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2831-5743","authenticated-orcid":false,"given":"Noemi","family":"Espurz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3955-5156","authenticated-orcid":false,"given":"Suleyman Eralp","family":"Bellibas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie St.","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"1629_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2020.101194","author":"J Rinke","year":"2020","unstructured":"Rinke J, Hochhaus A, Ernst T. CML - Not only BCR-ABL1 matters. Best Pract Res Clin Haematol. 2020. https:\/\/doi.org\/10.1016\/j.beha.2020.101194.","journal-title":"Best Pract Res Clin Haematol"},{"key":"1629_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26642","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol. 2022. https:\/\/doi.org\/10.1002\/ajh.26642.","journal-title":"Am J Hematol"},{"key":"1629_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35953","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Breccia M, Haddad FG, Hehlmann R, Issa GC, Malhotra H, et al. Management of chronic myeloid leukemia in 2025. Cancer. 2025. https:\/\/doi.org\/10.1002\/cncr.35953.","journal-title":"Cancer"},{"key":"1629_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27037","author":"FG Haddad","year":"2023","unstructured":"Haddad FG, Sasaki K, Bidikian A, Issa GC, Kadia T, Jain N, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol. 2023. https:\/\/doi.org\/10.1002\/ajh.27037.","journal-title":"Am J Hematol"},{"key":"1629_CR5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-219410","author":"FE Nicolini","year":"2009","unstructured":"Nicolini FE, Mauro MJ, Martinelli G, Kim DW, Soverini S, Muller MC, et al. Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood. 2009. https:\/\/doi.org\/10.1182\/blood-2009-04-219410.","journal-title":"Blood"},{"key":"1629_CR6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.080234","author":"FE Nicolini","year":"2013","unstructured":"Nicolini FE, Ibrahim AR, Soverini S, Martinelli G, Muller MC, Hochhaus A, et al. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica. 2013. https:\/\/doi.org\/10.3324\/haematol.2012.080234.","journal-title":"Haematologica"},{"key":"1629_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106458","author":"PW Manley","year":"2020","unstructured":"Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020. https:\/\/doi.org\/10.1016\/j.leukres.2020.106458.","journal-title":"Leuk Res"},{"key":"1629_CR8","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01040","author":"J Schoepfer","year":"2018","unstructured":"Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, et al. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. J Med Chem. 2018. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01040.","journal-title":"J Med Chem"},{"key":"1629_CR9","unstructured":"Scemblix (asciminib) Summary of Product Characteristics. Novartis, 2022. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/scemblix-epar-product-information_en.pdf. Accessed Mar 9, 2026."},{"key":"1629_CR10","unstructured":"Scemblix (asciminib). Prescribing information. Novartis Pharmaceuticals Corporation; 2025. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215358s010lbl.pdf. Accessed on Mar 9, 2026."},{"key":"1629_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-024-01428-6","author":"M Hoch","year":"2024","unstructured":"Hoch M, Huth F, Manley PW, Loisios-Konstantinidis I, Combes FP, Li YF, et al. Clinical pharmacology of Asciminib: a review. Clin Pharmacokinet. 2024. https:\/\/doi.org\/10.1007\/s40262-024-01428-6.","journal-title":"Clin Pharmacokinet"},{"key":"1629_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13285","author":"M Hoch","year":"2022","unstructured":"Hoch M, Huth F, Sato M, Sengupta T, Quinlan M, Dodd S, et al. Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents. Clin Transl Sci. 2022. https:\/\/doi.org\/10.1111\/cts.13285.","journal-title":"Clin Transl Sci"},{"key":"1629_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13357","author":"J Bolleddula","year":"2022","unstructured":"Bolleddula J, Gopalakrishnan S, Hu P, Dong J, Venkatakrishnan K. Alternatives to rifampicin: a review and perspectives on the choice of strong CYP3A inducers for clinical drug-drug interaction studies. Clin Transl Sci. 2022. https:\/\/doi.org\/10.1111\/cts.13357.","journal-title":"Clin Transl Sci"},{"key":"1629_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2652","author":"A van Haarst","year":"2023","unstructured":"van Haarst A, Smith S, Garvin C, Benrimoh N, Paglialunga S. Rifampin drug-drug-interaction studies: reflections on the Nitrosamine impurities issue. Clin Pharmacol Ther. 2023. https:\/\/doi.org\/10.1002\/cpt.2652.","journal-title":"Clin Pharmacol Ther"},{"key":"1629_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1611","author":"M Hoch","year":"2026","unstructured":"Hoch M, Weis W, Huth F, Jamalapuram S, Quinlan M, Bandaru A, et al. Assessment of pharmacokinetic drug interaction of Asciminib with Atorvastatin in healthy participants. Clin Pharmacol Drug Dev. 2026. https:\/\/doi.org\/10.1002\/cpdd.1611.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1629_CR16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902328","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019. https:\/\/doi.org\/10.1056\/NEJMoa1902328.","journal-title":"N Engl J Med"},{"key":"1629_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02278-8","author":"JE Cortes","year":"2024","unstructured":"Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, et al. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after \u22651 prior tyrosine kinase inhibitor: 2-year follow-up results. Leukemia. 2024. https:\/\/doi.org\/10.1038\/s41375-024-02278-8.","journal-title":"Leukemia"},{"key":"1629_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.01.017","author":"S Paglialunga","year":"2023","unstructured":"Paglialunga S, van Haarst A. The impact of N-nitrosamine impurities on clinical drug development. J Pharm Sci. 2023. https:\/\/doi.org\/10.1016\/j.xphs.2023.01.017.","journal-title":"J Pharm Sci"},{"key":"1629_CR19","unstructured":"FDA. Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers. Available at: https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Accessed Jul 31, 2025. 2023"},{"key":"1629_CR20","unstructured":"Dilantin (extended phenytoin sodium capsules). Prescribing information. Pfizer, 2022. Available at: https:\/\/labeling.pfizer.com\/showlabeling.aspx?id=546. Accessed Nov 6, 2025."},{"key":"1629_CR21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009984","author":"D Rea","year":"2021","unstructured":"Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021. https:\/\/doi.org\/10.1182\/blood.2020009984.","journal-title":"Blood"},{"key":"1629_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17101266","author":"I Loisios-Konstantinidis","year":"2025","unstructured":"Loisios-Konstantinidis I, Huth F, Hoch M, Einolf HJ. Physiologically based pharmacokinetic modeling and simulations in lieu of clinical pharmacology studies to support the new drug application of Asciminib. Pharmaceutics. 2025. https:\/\/doi.org\/10.3390\/pharmaceutics17101266.","journal-title":"Pharmaceutics"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01629-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01629-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01629-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:50:43Z","timestamp":1779119443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01629-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1629"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01629-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored and funded by Novartis Pharma AG, Basel, Switzerland.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors are employees of Novartis. MH, AT, FH, ILK, MQ, AK, DC, NE, and SEB are shareholders of Novartis. None of the authors declare any other conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study was conducted according to the International Council for Harmonisation E6 Guideline for Good Clinical Practice in accordance with the principles of the Declaration of Helsinki, as well as local laws and regulations. The study protocol and all amendments were reviewed by the Advarra institutional review board (Registration Number: 00000971).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants provided written informed consent before any study procedures were performed.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate (Study Participants)"}},{"value":"All participants provided written informed consent.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication (Study Participants)"}},{"value":"Novartis will not provide access to patient-level data if there is a reasonable likelihood that individual patients could be re-identified. Phase I studies, by their nature, present a high risk of patient re-identification; therefore, patient individual results for Phase I studies cannot be shared.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the conception and design of the research, data collection, analysis, and interpretation, as well as drafting, reviewing, and providing final approval of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}